

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

- 1-93. (Cancelled)
94. (New) An isolated polynucleotide selected from the group consisting of:
  - a. a polynucleotide sequence of SEQ ID NO:1;
  - b. a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1; and
  - c. a polynucleotide sequence complementary to either a) or b).
95. (New) An isolated polynucleotide selected from the group consisting of:
  - a. a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 2-7;
  - b. a naturally-occurring polynucleotide sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2-7; and
  - c. a polynucleotide sequence complementary to either a) or b).
96. (New) An isolated polypeptide sequence comprising an amino acid sequence selected from the group consisting of:
  - a. an amino acid sequence as set forth in any of SEQ ID NOS. 8, 28-37;
  - b. a naturally-occurring amino acid sequence having at least 90% sequence identity to any of the amino acid sequence of SEQ ID NOS. 8, 28-37;
  - c. a biologically active fragment of any of the amino acid sequence of SEQ ID NOS. 8, 28-37; and
  - d. an immunogenic fragment of the amino acid sequence of SEQ ID NOS. 8, 28-37.

97. (New) An isolated polypeptide fragment capable of generating an immune response against the SARS virus selected from the group consisting of

- a. a polypeptide sequence selected from the group consisting of SEQ ID NOs: 9-14;
- b. a naturally-occurring polypeptide sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 9-14.

98. (New) A vaccine effective against a human SARS virus infection comprising a peptide having a sequence selected from the group consisting of SEQ ID NOs: 1-7 and a pharmaceutically acceptable carrier.

99. (New) A vaccine effective against a human SARS virus infection comprising a peptide having a sequence selected from the group consisting of SEQ ID NOs: 8-14, 28-37 and a pharmaceutically acceptable carrier.

100. (New) A recombinant adenovirus expressing SARS viral proteins, comprising:

- a. an adenovirus, wherein portions of its sequence responsible for replication having been deleted, thus rendering the adenovirus incapable of replicating itself; and
- b. at least one polypeptide fragment selected from the group consisting of the spike protein, the small membrane protein, the small envelope protein, and the nuclear capsid protein.

101. (New) A recombinant adenovirus expressing SARS viral proteins, comprising:

- a. an adenovirus, wherein portions of its sequence responsible for replication having been deleted, thus rendering the adenovirus incapable of replicating itself; and
- b. two polypeptide fragments selected from the group consisting of the spike protein, the small membrane protein, the small envelope protein, and the nuclear capsid protein.

102. (New) A recombinant adenovirus expressing SARS viral proteins, comprising:

- a. an adenovirus, wherein portions of its sequence responsible for replication having been deleted, thus rendering the adenovirus incapable of replicating itself; and

- b. three polypeptide fragments selected from the group consisting of the spike protein, the small membrane protein, the small envelope protein, and the nuclear capsid protein.

103. (New) A recombinant adenovirus expressing SARS viral proteins, comprising:

- a. an adenovirus, wherein portions of its sequence responsible for replication having been deleted, thus rendering the adenovirus incapable of replicating itself; and
- b. a plurality of polypeptide fragments selected from the group consisting of the spike protein, the small membrane protein, the small envelope protein, and the nuclear capsid protein.

104. (New) A SARS vaccine comprising of the recombinant adenovirus of claim 100, and a pharmaceutically acceptable carrier.

105. (New) A method of modulating the immune response to human SARS virus infection, comprising administering an effective amount of the vaccine according to claim 104.

106. (New) A method of immunizing a subject against a SARS virus infection comprising administering to said subject the vaccine of claim 104.

107. (New) The method of claim 106, wherein said subject is a human.